Zinfandel Pharmaceuticals Inc.
Durham
North Carolina
United States
7 articles about Zinfandel Pharmaceuticals Inc.
-
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
-
Another experimental Alzheimer's disease treatment has failed in a late-stage study.
-
Takeda Pharmaceutical Co. Ltd. And Zinfandel Pharmaceuticals Inc. To Present Data At Upcoming Alzheimer's Association International Conference® Highlighting Innovative Approaches To Alzheimer's Disease Research And Development
7/10/2014
-
Takeda And Zinfandel Pharmaceuticals Inc. To Present Data At Upcoming Alzheimer’s Association International Conference® Highlighting Innovative Approaches To Alzheimer’s Disease Research And Development
7/10/2014
-
Takeda Pharmaceutical Co. Ltd. and Zinfandel Pharmaceuticals Inc. Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment
8/26/2013
-
Takeda and Zinfandel Pharmaceuticals Inc. Announce Results of a Study of the Performance Characteristics of a Genetics-Based Biomarker Risk Assignment Algorithm to Identify Risk of Mild Cognitive Impairment Due to Alzheimer's Disease
7/17/2013
-
Takeda Pharmaceutical Co. Ltd. and Zinfandel Pharmaceuticals Inc. Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone; Zinfandel to Receive $9M Upfront, Payments of up to $78M
1/11/2011